Antimalarial pharmacology and therapeutics of atovaquone.

J Antimicrob Chemother · 2013 · PMC4344550 · PMID 23292347

Europe PMC DOI

hedged sentence

0.1000

closest p · 2.0× alpha

0.1000

boldest claim

The sentences

showed a trendP < 0.1so close (0.05 < p ≤ 0.1)

76 Furthermore, patients taking atovaquone showed a trend towards lower zidovudine/glucuronide plasma concentrations (6% reduction in AUC 0-8 , P < 0.1) and a significant decrease in the ratio between zidovudine/glucuronide and plasma concentrations (30% reduction, P < 0.05).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.